

*Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or Japan.  
This press release does not constitute an offer of securities or a solicitation to buy, subscribe or sell securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.*

## **Onxeo announces the success of its Rights Issue with €9.7 million raised**

***This transaction will accelerate the development of the Company and its portfolio  
and extend its financial horizon to the end of 2022, beyond major clinical milestones  
expected in the next 18 months***

**Paris (France), April 12, 2021 – 7:00 pm CEST - Onxeo S.A.** (Euronext Growth Paris: ALONX; Nasdaq First North Growth Copenhagen: ONXEO, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announced the result of its capital increase through the issuance of new shares (the "**New Shares**") with shareholders' preferential subscription rights (PSR), whose subscription took place from March 19 to March 31, 2021 included in France and from March 19 to March 26, 2021 included in Denmark.

The gross amount of the capital increase, including the issue premium, amounted to 9.7 million euros and resulted in the creation of 13,677,125 New Shares, at a subscription price per share of 0.71 euro (5.287 DKK on the basis of an exchange rate of 7.447 DKK for 1 euro on March 9, 2021).

The proceeds from this issue of New Shares are intended to finance primarily the expansion and acceleration of the clinical development of AsiDNA™, in particular in combination with other anti-cancer agents.

The Company also intends to:

- continue the optimization and preclinical development of new candidates selected on the platON™ platform,
- optimize pharmaceutical development and compound manufacturing operations, and
- more generally, finance the Company's operations.

**Judith Greciet, CEO of Onxeo, said:** *"We would like to thank all our investors, both historical and new, who have contributed to the success of this fundraising. The renewed confidence in our long-term strategy by our two core shareholders, Financière de la Montagne and Invus, as well as by many other shareholders, secures the ramp-up of our development and extends our visibility until the end of 2022. With the funds raised, the Company will accelerate the development of AsiDNA™ with other clinical trials, notably in non-small cell lung cancer, with a phase 2 study designed to be extended as a potential pivotal trial. The clinical program should also include the United States as part of the acceleration plan. Additionally, we will expand our portfolio with other compounds from our platON™ platform."*

The Board of Directors of Onxeo, in its meeting on April 12, 2021, recorded the amount of subscriptions and decided on the final terms of the capital increase with preferential subscription rights of shareholders decided on March 9, 2021.

### **RESULT OF THE RIGHT ISSUE**

At the end of the subscription period, subscriptions totaled 13,677,125 shares, divided as follows:

- 6,111,797 New Shares were subscribed on an irreducible basis;
- 7,565,328 Shares News were requested on a free basis.

As the Company has decided to exercise the extension clause provided for in the 20<sup>th</sup> resolution of the General Meeting of June 19, 2020 for 4.8% of the initial offer, the new shares applied for on a free basis were fully allocated.



*Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or Japan.  
This press release does not constitute an offer of securities or a solicitation to buy, subscribe or sell securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.*

Consequently, the gross amount of the capital increase, including issue premium, amounts to 9,710,758.75 euros and results in the issue of 13,677,125 new shares, at a unit subscription price of 0.71 euros, corresponding to a subscription rate of approximately 104.8%.

The Company's share capital following the capital increase will amount to 22,998,733.75 euros, divided into 91,994,935 shares with a par value of 0.25 euros each.

The settlement-delivery of the New Shares and their admission to trading on Euronext Growth Paris and Nasdaq First North Growth Copenhagen are scheduled for April 16 and April 19, 2021, respectively.

The New Shares will carry dividend rights and will be traded on the same quotation line as the existing shares (ISIN FR0010095596).

### **Impact of the issue on the shareholding structure**

The following table presents the distribution of capital, to the Company's knowledge, before and after the completion of the capital increase.

The commitments of the existing shareholders, Financière de la Montagne and Invus Public Equities LP, were fully subscribed for a total amount of 7 million euros, respectively 3 and 4 of which approximately 2.1 million euros were on an irreducible basis and 4.9 million euros on a free basis. The subscriptions of other investors thus amount to about 2.7 million euros.

Actionnaires	Number of shares before the issue	% of capital and voting rights(1) shares before the issue	Number of shares after the issue	% of capital and voting rights(1) shares after the issue
Financière de la Montagne	10,462,560	13.36%	14,708,767	15.99%
Invus Public Equities LP	8,397,270	10.72%	14,031,073	15.25%
Free float	59,457,980	75.92%	63,255,095	68.76%
<b>Total</b>	<b>78,317,810</b>	<b>100.00%</b>	<b>91,994,935</b>	<b>100.00%</b>

(1) Theoretical voting rights. All shares have the same voting rights, with the exception of treasury shares held by the Company.

### **DILUTION**

For information purposes, the impact of the issue on the capital ownership of a shareholder holding 1% of the Company's share capital prior to the issue and who did not subscribe to the issue (calculations based on a number of 78,317,810 shares making up the Company's share capital at December 31, 2020) is as follows:

(en euro par action)	Shareholder's interest (%)	
	Non-diluted basis	Diluted basis (1)
Before issue of New Shares	1.00	0.95
After issue of 13,677,125 New Shares	0.85	0.81

(1) Taking into account the 4,335,740 options and warrants giving access to the share capital granted and outstanding as of today.

### **INDICATIVE TIMETABLE OF THE OPERATION**

April 16, 2021	Issuance of New Shares – Settlement and Delivery.
April 19, 2021	Admission of the New Shares to trading on Euronext Growth Paris and Nasdaq First North Growth Copenhagen.



*Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or Japan. This press release does not constitute an offer of securities or a solicitation to buy, subscribe or sell securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.*

### **Contributors**

- Invest Securities acted as Lead Manager and Bookrunner of the transaction.
- Invest Corporate Finance acted as Listing Sponsor.
- Nordea Denmark, a subsidiary of Nordea Bank Abp, Finland, acted as underwriting agent in Denmark.

### **AVAILABILITY OF THE PROSPECTUS**

The Prospectus, having received the approval n°21-063 dated March 9, 2021 from the Autorité des marchés financiers ("AMF"), consists of (i) the Universal Registration Document of Onxeo filed with the AMF on April 27, 2020 under number D.20-0362 (the "**Universal Registration Document**"), (ii) the Amendment to the Universal Registration Document, filed with the AMF on March 9, 2021 under number D.20-0362-A01, (iii) a Securities Note and (iv) a summary of the Prospectus (included in the Securities note).

Copies of the Prospectus are available free of charge at the registered office of Onxeo, 49, boulevard du Général Martial Valin - 75015 Paris. The Prospectus may also be consulted on the websites of the AMF ([www.amf-france.org](http://www.amf-france.org)) and Onxeo ([www.onxeo.com](http://www.onxeo.com)) and from the Lead Manager and Bookrunner.

In connection with the opening of the public offering in Denmark, an unofficial translation into English of all the documents constituting the prospectus has also been prepared by the Company. In the event of any discrepancy between the French prospectus and the English translation, the French version will prevail. These documents are also available free of charge at Onxeo's registered office at 49, boulevard du Général Martial Valin - 75015 Paris and on Onxeo's website ([www.onxeo.com](http://www.onxeo.com)).

### **Risk Factors**

Investors are invited to carefully consider the risk factors detailed in section 3 of the Universal Registration Document, section 2 of the Amendment to the Universal Registration Document and section 2 of the Securities Note. The occurrence of all or part of these risks may have an adverse effect on the Group's business, financial position, results or ability to achieve its objectives.

### **About Onxeo**

**Onxeo** (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

**platON™** is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.

**AsiDNA™**, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered Intravenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin +/- paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy). A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie).



*Do not distribute or disseminate, directly or indirectly, in the United States of America, Canada, Australia or Japan.  
This press release does not constitute an offer of securities or a solicitation to buy, subscribe or sell securities in the United States of America or in any other jurisdiction in which it would be unlawful to do so.*

**OX401** is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit [www.onxeo.com](http://www.onxeo.com).

### Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to chapter 3 "Risk Factors" ("*Facteurs de Risque*") of the Company's universal registration document filed with the *Autorité des marchés financiers* on April 27, 2020 under number D.20-0362 and to section 2 of the Amendment to the Universal Registration Document, filed with the AMF on March 9, 2021 under number D.20-0362-A01, which are available on the websites of the *Autorité des marchés financiers* ([www.amf-france.org](http://www.amf-france.org)) and the Company ([www.onxeo.com](http://www.onxeo.com)).

### Contacts

#### Onxeo

Valerie Leroy,  
Investor Relations  
[investors@onxeo.com](mailto:investors@onxeo.com)  
+33 1 45 58 76 00

#### Media Relations

Nicolas Merigeau  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 98

#### Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 92

### Certified Adviser for Nasdaq First North

Kapital Partner  
[www.kapitalpartner.dk](http://www.kapitalpartner.dk)  
[info@kapitalpartner.dk](mailto:info@kapitalpartner.dk)  
+45 89 88 78 46